Last reviewed · How we verify
NCT06693895
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
Phase 3 trial testing Investigational varicella vaccine in Chickenpox in 750 participants. Currently enrolling.
1 July 2026
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 750 |
| Start date | 26 November 2024 |
| Primary completion | 1 July 2026 |
| Estimated completion | 23 November 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Investigational varicella vaccine — full drug profile →
- Marketed varicella vaccine — full drug profile →
- Measles, mumps, and rubella vaccine
- Hepatitis A vaccine — full drug profile →
- PCV (pneumococcal conjugate vaccine) 13
- PCV 20 — full drug profile →
- Vaxneuvance — full drug profile →
Conditions studied
- Chickenpox — all drugs for Chickenpox →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
Adults 12 Months to 15 Months, any sex, with Chickenpox. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06693895
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Investigational varicella vaccine
Trials testing the same drug.
- NCT06806137 — A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Heal · Phase 3 · recruiting
Other recruiting trials for Chickenpox
Currently open trials in the same condition.
- NCT06806137 — A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Heal · Phase 3 · recruiting
- NCT06855160 — A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rub · Phase 3 · recruiting
- NCT06740630 — A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to · Phase 3 · recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06693895 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 20 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06693895.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing